Digbi Health has launched ASRA, a platform using AI agents to handle outreach, enrollment, engagement and personalized nutrition guidance across obesity, diabetes, hypertension, gut health and menopause programs, with clinicians retaining all clinical decisions. Personalization draws on member-level microbiome, genetic, laboratory, claims, continuous glucose monitoring and device data accumulated over three years. The claims of superior personalization and consolidation efficiency are company-stated and not yet supported by published comparative outcomes.
Key Points
- AI agents handle outreach and engagement; clinicians retain clinical decisions
- Microbiome, genetic, glucose and claims data drive individualized guidance
- Personalization and outcome claims remain company-reported, not independently validated
Longevity Analysis
Fragmented care programs produce fragmented physiology — metabolic weight management, glucose regulation and midlife hormonal shifts are treated as separate problems when they share underlying mechanisms. Consolidating microbiome, genomic, continuous glucose and laboratory data into a single interpretive layer improves the chance that a signal gets read correctly rather than assigned to whichever vendor happens to own the symptom. The limiting factor in most metabolic programs has never been the protocol but sustained participation, and automating the engagement layer addresses precisely that gap, provided the personalization claims are eventually verified against outcomes.
Original published by Longevity.Technology, by Kyle Umipig.